Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner

Skin and Mucosal Delivery (Focus Group – SMD)

Recombinant Human Hyaluronidase Improves PK of Subcutaneous ADC: Comparative Minipig Evaluation

Robert Connor – Senior Principal Scientist, Halozyme Therapeutics; Ryan Nolan – Senior Director, Halozyme Therapeutics; Tara Nekoroski – Director, Halozyme Therapeutics; Limin Liu – Senior Scientist, Halozyme Therapeutics; Yan Wang – Senior Director, Halozyme Therapeutics; Marie Printz – Executive Director, Halozyme Therapeutics; Chris Wahl – Chief Scientific Officer, Halozyme Therapeutics

    Poster Presenter(s)

  • David Kang, PhD

    Director, Drug Delivery and Innovation
    Halozyme Therapeutics
    San Diego, California, United States

Introduction: Subcutaneous (SC) delivery of antibody-drug conjugates (ADCs) offers a patient-friendly alternative to intravenous (IV) infusion but is potentially limited by slow absorption and variable bioavailability. Recombinant human hyaluronidase PH20 (rHuPH20) transiently degrades hyaluronan, enabling rapid dispersion of large-volume injections, and improving absorption [1]. This study assessed the impact of rHuPH20 on the pharmacokinetics (PK) of sacituzumab govitecan (SG) and trastuzumab deruxtecan (TD) following SC delivery in minipigs.

Learning Objectives:

  • Understand PK limits of subcutaneous ADC delivery and mechanisms by which rHuPH20 improves absorption.
  • Compare PK outcomes for SG and TD administered SC with and without rHuPH20.
  • Assess rHuPH20-enabled SC administration as an alternative to IV dosing for ADCs.